Stockscreener 앱 받기
13.96
5.36%
0.72
시간 외 거래:
13.69
-0.27
-1.93%
Denali Therapeutics Inc 주식(DNLI)의 최신 뉴스
(DNLI) On The My Stocks Page - news.stocktradersdaily.com
Stifel maintains Buy on Denali Therapeutics stock, $37 target - Investing.com Australia
Stifel Nicolaus Reaffirms Their Buy Rating on Denali Therapeutics (DNLI) - The Globe and Mail
Stifel maintains Buy on Denali Therapeutics stock, $37 target By Investing.com - Investing.com UK
Sanfilippo syndrome Pipeline 2025: Groundbreaking Clinical - openPR.com
When (DNLI) Moves Investors should Listen - news.stocktradersdaily.com
Hunter Syndrome Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
Metachromatic Leukodystrophy Pipeline 2025: Groundbreaking - openPR.com
Denali Therapeutics (DNLI) Receives a Price Target Adjustment fr - GuruFocus
Denali Therapeutics (DNLI) Receives a Price Target Adjustment from B of A Securities | DNLI Stock News - GuruFocus
Denali Therapeutics (DNLI) Target Price Adjusted by Analyst | DN - GuruFocus
Denali Therapeutics shares fall after price target cut to $32 By Investing.com - Investing.com Nigeria
Where are the Opportunities in (DNLI) - news.stocktradersdaily.com
Denali Q1 Loss Wider Than Expected, Hunter Syndrome Drug in Focus - MSN
Hunter Syndrome Treatment Market Expands with Enzyme - openPR.com
Denali Therapeutics (DNLI) Price Target Reduced to $30 by Analys - GuruFocus
Denali Therapeutics shares fall after price target cut to $32 - Investing.com
Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth - Yahoo Finance
Denali Therapeutics (DNLI) Price Target Revised Amid Strategic D - GuruFocus
Denali Therapeutics Advances Pipeline Amid Financial Loss - TipRanks
Denali Therapeutics (DNLI) Target Price Adjusted by HC Wainwrigh - GuruFocus
Denali Therapeutics (DNLI) Target Price Adjusted by HC Wainwright & Co. | DNLI Stock News - GuruFocus
Denali Therapeutics (DNLI) Price Target Revised Amid Strategic Developments | DNLI Stock News - GuruFocus
Denali Therapeutics price target lowered to $32 from $80 at H.C. Wainwright - TipRanks
Decoding Denali Therapeutics Inc (DNLI): A Strategic SWOT Insigh - GuruFocus
Denali Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Denali Therapeutics Reports First Quarter 2025 Financial - GlobeNewswire
Breakthrough Hunter Syndrome Drug Heads to FDA: Denali's Brain-Barrier Treatment Could Transform Patient Care - Stock Titan
5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates - TradingView
Biogen (BIIB) Completes Enrollment for Parkinson's Treatment Stu - GuruFocus
First Week of December 19th Options Trading For Denali Therapeutics (DNLI) - Nasdaq
(DNLI) Technical Data - news.stocktradersdaily.com
Amyotrophic Lateral Sclerosis Pipeline 2025: MOA and ROA - openPR.com
Amyotrophic Lateral Sclerosis Pipeline 2025: MOA and ROA Insights, Clinical Trials, and Key Companies Involved by DelveInsight | Biogen, GSK, Helixmith, Sanofi, Denali Therapeutics, Ionis Pharma - The Globe and Mail
Denali Announces Rolling Regulatory Submission of Tividenofusp Alfa for Hunter Syndrome - Neurology live
Denali Therapeutics stock hits 52-week low at $12.05 - Investing.com Australia
Denali Therapeutics stock hits 52-week low at $12.05 By Investing.com - Investing.com Canada
Frontotemporal Dementia Pipeline 2025: Key Companies, MOA, - openPR.com
DNLI Begins Rolling BLA Submission for Hunter Syndrome Drug, Stock Up - Zacks Investment Research
Denali Therapeutics set to advance groundbreaking treatments for neurological diseases - MSN
Denali Therapeutics advances Hunter syndrome treatment BLA By Investing.com - Investing.com South Africa
What Happened To Denali Therapeutics Stock Wednesday? - Benzinga
Sector Update: Health Care Stocks Advance in Late Afternoon Trading - TradingView
Sector Update: Health Care - MarketScreener
Denali Therapeutics begins marketing application for genetic disorder drug, shares rise - TradingView
Denali Goes All In on Neuroscience’s Thorniest Hurdle: Crossing the Blood-Brain Barrier - BioSpace
Denali Therapeutics Files Application for Accelerated Approval of Hunter Syndrome Treatment; Shares Up - MarketScreener
How another firm's FDA approval could mean a big win for Denali TherapeuticsSan Francisco Business Times - The Business Journals
Denali Therapeutics Announces Initiation of BLA Filing for - GlobeNewswire
Denali Therapeutics advances Hunter syndrome treatment BLA - Investing.com
6.29%
자본화:
|
볼륨(24시간):